EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

IDH1/2 Mutations in Cancer: Unifying Insights and Unlocking Therapeutic Potential for Chondrosarcoma

Shriya Deshmukh, Ciara Kelly, Gabriel Tinoco

Targeted Oncology · 2025

DOI: 10.1007/s11523-024-01115-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Targeted Oncology, 2025. Verfasst von Shriya Deshmukh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, The Ohio State University, Columbus, OH, USA. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Chondrosarcoma, Bone Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chondrosarcomas, a rare form of bone sarcomas with multiple subtypes, pose a pressing clinical challenge for patients with advanced or metastatic disease. The lack of US Food and Drug Administration (FDA)-approved medications underscores the urgent need for further research and development in this area. Patients and their families face challenges as there are no systemic therapeutic options available with substantial effectiveness. A significant number (50-80%) of chondrosarcomas have a mutation in the isocitrate dehydrogenase (IDH) genes. This review focuses on IDH-mediated pathogenesis and recent pharmacological advances with novel IDH inhibitors, explores their potential therapeutic value, and proposes potential future avenues for clinical trials combining IDH inhibitors with other systemic agents for chondrosarcomas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Isocitrate DehydrogenaseChondrosarcomaBone NeoplasmsHumansMutation

Substanzen

Isocitrate DehydrogenaseIDH1 protein, humanIDH2 protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
  • Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Division of Medical Oncology, The Ohio State University, Columbus, OH, USA. Gabriel.Tinoco@osumc.edu.

Förderung

  • NCI NIH HHS

Zitieren

APA

Deshmukh, S., Kelly, C., & Tinoco, G. (2025). IDH1/2 Mutations in Cancer: Unifying Insights and Unlocking Therapeutic Potential for Chondrosarcoma. Targeted Oncology. https://doi.org/10.1007/s11523-024-01115-3

Vancouver

Deshmukh S, Kelly C, Tinoco G. IDH1/2 Mutations in Cancer: Unifying Insights and Unlocking Therapeutic Potential for Chondrosarcoma. Targeted Oncology. 2025. doi:10.1007/s11523-024-01115-3

BibTeX
@article{Deshmukh2025,
  author = {Deshmukh, Shriya and Kelly, Ciara and Tinoco, Gabriel},
  title = {IDH1/2 Mutations in Cancer: Unifying Insights and Unlocking Therapeutic Potential for Chondrosarcoma},
  journal = {Targeted Oncology},
  year = {2025},
  doi = {10.1007/s11523-024-01115-3}
}
Kostenlos starten →